医薬品インタビューフォーム - mylan.co.jp

1 2017 2 9 872399 IF (1998 9 ) 500 1 500 1g 833 JAN Polycarbophil calcium JAN Polycarbophil INN 500 2000 7 3 2000 8 25 2000 10 18 2008 2 28 2008 6 20 2000 10 18 FAX IF 2017 2 1 63

2 10 2 3 11 4 Drug Safety Update i I 1 1 1 2 1 II 2 1

3 2 2 2 3 2 4 2 5 2 6 2 7 CAS 3 III 4 1 4 2 4 3 5 4 5 5 5 IV 6 1 6 2 6 3 6 4 7 5 8 6 8 7 8 8 8 9

4 9 10 9 11 9 12 9 13 9 14 9 ii V 10 1 10 2 10 3 11 VI 13 1 13 2 13 VII 29 1 29 2 29 3 30 4 31 5 31 6 32 7 33 8

5 33 VIII 35 1 35 2 35 3 36 4 36 5 38 6 39 7 40 8 41 9 44 10 44 11 44 12 44 13 44 14 44 15 45 16 45 iii IX 46 1 46 2 47 X 50 1 50 2

6 50 3 50 4 50 5 50 6 50 7 50 8 50 9 51 10 51 11 51 12 51 13 51 14 51 15 51 XI 52 1 52 2 52 XII 53 53 XIII 54 54

7 55 55 1 I 1 Irritable Bowel Syndrome IBS IBS IBS Quality of Life QOL IBS IBS IBS 3,4- -1.

8 5- 12 2000 7 OTC 2 751 66 3,096 68 2 II 1 (1) 500 (2) Polyful Tablets 500 Polyful Fine Granules (3) 2 (1) JAN (2)

9 Polycarbophil calcium JAN Polycarbophil INN 3 4 6 6 a 4 a 6 10 2 b 5 3,4- -1,5- Calcium salt of polyacrylic acid cross-linked with 3,4-dihydroxy-1,5- hexadiene 6 HSR 237 HSR 237G CH 2 CHC H 2 C H CHOH CHOH C H C H 2 COO - 1 / 2 C a 2 + a b 3 7 CAS 126040-58-2 4 III 1 2 (1) (2) 20 C 1g mL